ADMA BIOLOGICS INC (ADMA) Fundamental Analysis & Valuation

NASDAQ:ADMA • US0008991046

15.79 USD
-0.75 (-4.53%)
Last: Mar 5, 2026, 10:31 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ADMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ADMA. ADMA was compared to 520 industry peers in the Biotechnology industry. ADMA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on ADMA. These ratings would make ADMA suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

7

1. ADMA Profitability Analysis

1.1 Basic Checks

  • ADMA had positive earnings in the past year.
  • In the past year ADMA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ADMA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • The Return On Assets of ADMA (23.54%) is better than 97.12% of its industry peers.
  • ADMA has a Return On Equity of 30.78%. This is amongst the best in the industry. ADMA outperforms 96.92% of its industry peers.
  • ADMA's Return On Invested Capital of 27.76% is amongst the best of the industry. ADMA outperforms 98.65% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ADMA is in line with the industry average of 19.05%.
  • The last Return On Invested Capital (27.76%) for ADMA is above the 3 year average (20.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 28.80%, ADMA belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
  • ADMA has a Operating Margin of 37.52%. This is amongst the best in the industry. ADMA outperforms 97.12% of its industry peers.
  • Looking at the Gross Margin, with a value of 57.39%, ADMA is in the better half of the industry, outperforming 77.69% of the companies in the same industry.
  • ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ADMA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
  • The number of shares outstanding for ADMA has been increased compared to 1 year ago.
  • ADMA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ADMA has been reduced compared to a year ago.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ADMA has an Altman-Z score of 18.32. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • ADMA's Altman-Z score of 18.32 is amongst the best of the industry. ADMA outperforms 88.27% of its industry peers.
  • The Debt to FCF ratio of ADMA is 2.62, which is a good value as it means it would take ADMA, 2.62 years of fcf income to pay off all of its debts.
  • ADMA has a better Debt to FCF ratio (2.62) than 93.08% of its industry peers.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • ADMA has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: ADMA underperforms 63.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 18.32
ROIC/WACC3.18
WACC8.73%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • ADMA has a Current Ratio of 6.71. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • ADMA has a better Current ratio (6.71) than 67.88% of its industry peers.
  • ADMA has a Quick Ratio of 3.74. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • ADMA's Quick ratio of 3.74 is in line compared to the rest of the industry. ADMA outperforms 47.12% of its industry peers.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADMA Growth Analysis

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
  • Looking at the last year, ADMA shows a quite strong growth in Revenue. The Revenue has grown by 19.63% in the last year.
  • Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 64.62% on average per year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.23% on average per year.
  • ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.85% yearly.
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

7

4. ADMA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 26.32, the valuation of ADMA can be described as expensive.
  • Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 92.69% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of ADMA to the average of the S&P500 Index (27.03), we can say ADMA is valued inline with the index average.
  • A Price/Forward Earnings ratio of 17.11 indicates a rather expensive valuation of ADMA.
  • Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.23% of the companies in the same industry.
  • ADMA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.32
Fwd PE 17.11
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.65% of the companies listed in the same industry.
  • 91.15% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 136.72
EV/EBITDA 19.66
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • ADMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ADMA may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 38.57% in the coming years.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y41.43%
EPS Next 3Y38.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMA Dividend Analysis

5.1 Amount

  • No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA Fundamentals: All Metrics, Ratios and Statistics

ADMA BIOLOGICS INC

NASDAQ:ADMA (3/5/2026, 10:31:02 AM)

15.79

-0.75 (-4.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.5%
Inst Owner Change-2.89%
Ins Owners2.35%
Ins Owner Change3.92%
Market Cap3.76B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts82.22
Price Target26.18 (65.8%)
Short Float %9.25%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 26.32
Fwd PE 17.11
P/S 7.37
P/FCF 136.72
P/OCF 74.62
P/B 7.88
P/tB 7.95
EV/EBITDA 19.66
EPS(TTM)0.6
EY3.8%
EPS(NY)0.92
Fwd EY5.85%
FCF(TTM)0.12
FCFY0.73%
OCF(TTM)0.21
OCFY1.34%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.49
PEG (5Y)N/A
Graham Number5.2
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 18.32
F-Score6
WACC8.73%
ROIC/WACC3.18
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.74%
EBIT Next 3Y42.39%
EBIT Next 5Y35.13%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.